TY - JOUR
T1 - A quality evaluation of the clinical practice guidelines on breast cancer using the RIGHT checklist
AU - Zhou, Hanqiong
AU - Chen, Haiyang
AU - Cheng, Cheng
AU - Wu, Xuan
AU - Ma, Yanfang
AU - Han, Jing
AU - Li, Ding
AU - Lim, Geok Hoon
AU - Rozen, Warren M.
AU - Ishii, Naohiro
AU - Roy, Pankaj G.
AU - Wang, Qiming
N1 - Funding Information:
This work was supported by Henan Province Health and Youth Subject Leader Training Project ([2020]60); Leading Talent Cultivation Project of Henan Health Science and Technology Innovation Talents (YXKC2020009); ZHONGYUAN QIANREN JIHUA (ZYQR201912118); Henan International Joint Laboratory of drug resistance and reversal of targeted therapy for lung cancer ([2021]10); Henan Medical Key Laboratory of Refractory lung cancer ([2020]27); Henan Refractory Lung Cancer Drug Treatment Engineering Technology Research Center ([2020]4); the 51282 project Leading Talent of Henan Provincial Health Science and Technology Innovation Talents ([2016]32); Huilan Charity Funda project (HL-HS2020-129).
Publisher copyright:
© Annals of Translational Medicine. All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - Background: Breast cancer is the
most frequent type of cancer in women. The methodological quality of
clinical practice guidelines (CPGs) on breast cancer has been shown to
be heterogeneous. The aim of our study was to evaluate the quality of
breast cancer CPGs published in years 2018-2020, using the Reporting
Items for Practice Guidelines in Healthcare (RIGHT) checklist.Methods: We
searched Medline (via PubMed), Chinese National Knowledge
Infrastructure (CNKI), Wanfang and Chinese Biomedical Literature (CBM)
as well as websites of guideline organizations for CPGs on breast cancer
published between 2018 and 2020. We used the RIGHT checklist to
evaluate the reporting quality of the included guidelines by assessing
whether the CPGs adhered to each item of the checklist and calculated
the proportions of appropriately reported RIGHT checklist items. We also
presented the adherence reporting rates for each guideline and the mean
rates for each of the seven domains of the RIGHT checklist.Results: A
total of 45 guidelines were included. Eighteen (40.0%) guidelines had
an overall reporting rate below 50% and only three (6.7%) reported more
than 80% of the items. The domains “Basic information” and “Background”
had the highest reporting rates (75.9% and 62.5%, respectively). The
mean reporting rates of the domains “Evidence”, “Recommendation”,
“Review and quality assurance”, “Funding and declaration and management
of interests” and “Other information” were 42.7%, 53.0%, 33.3%, 45.0%,
and 44.4%, respectively.Conclusions: The
reporting quality varied among guidelines for breast cancer, showing the
need for improvement in reporting the contents. Guideline developers
should pay more attention to reporting the evidence, review and quality
assurance, and funding and declaration and management of interests in
future.
AB - Background: Breast cancer is the
most frequent type of cancer in women. The methodological quality of
clinical practice guidelines (CPGs) on breast cancer has been shown to
be heterogeneous. The aim of our study was to evaluate the quality of
breast cancer CPGs published in years 2018-2020, using the Reporting
Items for Practice Guidelines in Healthcare (RIGHT) checklist.Methods: We
searched Medline (via PubMed), Chinese National Knowledge
Infrastructure (CNKI), Wanfang and Chinese Biomedical Literature (CBM)
as well as websites of guideline organizations for CPGs on breast cancer
published between 2018 and 2020. We used the RIGHT checklist to
evaluate the reporting quality of the included guidelines by assessing
whether the CPGs adhered to each item of the checklist and calculated
the proportions of appropriately reported RIGHT checklist items. We also
presented the adherence reporting rates for each guideline and the mean
rates for each of the seven domains of the RIGHT checklist.Results: A
total of 45 guidelines were included. Eighteen (40.0%) guidelines had
an overall reporting rate below 50% and only three (6.7%) reported more
than 80% of the items. The domains “Basic information” and “Background”
had the highest reporting rates (75.9% and 62.5%, respectively). The
mean reporting rates of the domains “Evidence”, “Recommendation”,
“Review and quality assurance”, “Funding and declaration and management
of interests” and “Other information” were 42.7%, 53.0%, 33.3%, 45.0%,
and 44.4%, respectively.Conclusions: The
reporting quality varied among guidelines for breast cancer, showing the
need for improvement in reporting the contents. Guideline developers
should pay more attention to reporting the evidence, review and quality
assurance, and funding and declaration and management of interests in
future.
KW - Breast cancer
KW - clinical practice guideline
KW - Reporting Items for Practice Guidelines in Healthcare checklist (RIGHT checklist)
KW - reporting quality
U2 - 10.21037/atm-21-2884
DO - 10.21037/atm-21-2884
M3 - Journal article
C2 - 34430615
SN - 2305-5839
VL - 9
JO - Annals of translational medicine
JF - Annals of translational medicine
IS - 14
M1 - 1174
ER -